April 5, 2022 New logo! Rare Disease Cures Accelerator-Data and Analytics Platform has a new look! C-Path’s RDCA-DAP team is excited to unveil its new logo for the Rare Disease Cures Accelerator-Data and Analytics Platform
April 5, 2022 C-Path Receives Qualification Opinion from EMA on Type 1 Diabetes Biomarker Initiative TUCSON, Ariz., April 5, 2022 — Critical Path Institute’s (C-Path) Type 1 Diabetes Consortium (T1DC) today announced that the E
April 2, 2022 eCOA Consortium and PRO Consortium Announce Publication of Open Access Article C-Path’s eCOA Consortium and PRO Consortium are pleased to announce that “Recommendations for the Electronic Migration and
March 28, 2022 Digital Health Technologies for Remote Data Acquisition in Clinical Investigations C-Path thanks and commends FDA for inviting public comments as part of the creation of a guidance document for Digital Health...
March 28, 2022 C-Path is proud to share our responses to the FDA draft guidance, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations The Clinical Outcomes Assessment (COA), Critical Path for Parkinson’s Digital Drug Development (3DT) Initiative, and Type 1 Diab
March 23, 2022 C-Path European Nonprofit Established in Amsterdam C-Path in Europe works seamlessly with its U.S. counterpart to advance the development of novel regulatory-endorsed methodologies
March 21, 2022 Recommendations to Optimize the Use of Volumetric MRI in Huntington’s Disease in Clinical Trials
March 21, 2022 Recommendations to Optimize the Use of Volumetric MRI in Huntington’s Disease in Clinical Trials C-Path’s Huntington’s Disease Regulatory Science Consortium (HD-RSC) has published a new paper on volumetric MRI-based biomark
March 18, 2022 Movement Disorders Congress 2021 | Presentations on behalf of CPP Critical Path for Parkinson’s members, advisors and staff submitted six posters on behalf of CPP and CPP’s digital effort, Dig
